ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1603

Stroke Clusters in SLE by Lupus Autoantibodies

Michelle Petri1 and Daniel Goldman 2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: stroke and autoantibodies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Stroke is the most common arterial thrombotic event in SLE. It is known to be associated with antiphospholipid antibodies, but clinicians have additional concern about the contribution of SLE. We performed the first cluster analysis of stroke in a longitudinal SLE cohort.

Methods: There were 245 strokes in SLE patients confirmed by brain CT or MRI. Patients were 93.5% female, 50.5% Caucasian, and 45.3% African-American. Age at time of stroke was 41.5 ± 15.0 years (mean ± SD). Autoantibodies included lupus anticoagulant (dRVVT with confirmatory testing), anticardiolipin, anti-dsDNA, low C3, low C4, anti-Sm, anti-RNP, anti-Ro and anti-La. Analyses were done both without (Table 1, 214 patients) and with (Table 2, 145 patients) anti-beta2 glycoprotein 1, due to more missing data on anti-beta2 glycoprotein 1. Clustering was performed using Ward’s Hierarchical Clustering method (JMP v 13.0.0, SAS Institute Inc).

Results: Five clusters were identified. Cluster 5 (Table 1) and cluster 4 (Table 2) are an antiphospholipid cluster without strong serologic activity. Cluster 4 (Table 1) and Cluster 5 (Table 2) are clusters without antiphospholipid and without serologic activity. Clusters 1, 2 and 3 (Table 1) and clusters 2, 3 and to some extent cluster 1 (Table 2) are clusters with serologic activity. Clusters 2 and 3 (Table 1) and cluster 2 (Table 2) have strong anti-Sm and anti-RNP markers, and are associated with more African-American ethnicity compared to the other clusters combined (63.3% vs 42.3%, p=0.0136).

Conclusion: Stroke clustering identified 4 major serologic backgrounds for stroke in SLE: antiphospholipid alone, serologic markers alone, both antiphospholipid and serologic, and a group with neither. Some clusters represent stroke in predominantly African-American patients. These clusters may be helpful in formulating risk scores for stroke in SLE, in risk prevention, and eventually might be useful in treatment.


ACR 2019-Stroke Clusters in SLE by Lupus Autoantibodies-Table1

Cluster Analysis of Stroke Patients without Anti-beta2 GP1


ACR 2019-Stroke Clusters in SLE by Lupus Autoantibodies-Table2

Cluster Analysis of Stroke Patients with Anti-beta2 GP1


Disclosure: M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Goldman D. Stroke Clusters in SLE by Lupus Autoantibodies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/stroke-clusters-in-sle-by-lupus-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stroke-clusters-in-sle-by-lupus-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology